{"DataElement":{"publicId":"7582657","version":"1","preferredName":"Anus High Grade Squamous Intraepithelial Neoplasia Prior Therapeutic Procedure Number","preferredDefinition":"Number of prior therapeutic procedures for anal high-grade squamous intraepithelial lesions (HSIL) the participant has received.","longName":"AHSIL_TRTNUM","context":"AMC","contextVersion":"1","DataElementConcept":{"publicId":"7582651","version":"1","preferredName":"Anus High Grade Squamous Intraepithelial Neoplasia Prior Therapeutic Procedure","preferredDefinition":"The lower opening of the digestive tract, lying in the cleft between the buttocks, through which fecal matter is extruded._A precancerous neoplastic process characterized by the presence of moderate or severe dysplastic cytological changes which extend to the upper part of the squamous epithelium.  Maturation at the surface of the squamous epithelium may or may not be present.  Representative examples include the high grade esophageal squamous intraepithelial neoplasia, high grade cervical squamous intraepithelial neoplasia, high grade vaginal intraepithelial neoplasia, and high grade vulvar intraepithelial neoplasia._Earlier in time or order._An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","longName":"7582646v1.0:2736850v1.0","context":"AMC","contextVersion":"1","ObjectClass":{"publicId":"7582646","version":"1","preferredName":"Anus High Grade Squamous Intraepithelial Neoplasia","preferredDefinition":"The lower opening of the digestive tract, lying in the cleft between the buttocks, through which fecal matter is extruded.:A precancerous neoplastic process characterized by the presence of moderate or severe dysplastic cytological changes which extend to the upper part of the squamous epithelium.  Maturation at the surface of the squamous epithelium may or may not be present.  Representative examples include the high grade esophageal squamous intraepithelial neoplasia, high grade cervical squamous intraepithelial neoplasia, high grade vaginal intraepithelial neoplasia, and high grade vulvar intraepithelial neoplasia.","longName":"C43362:C8336","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anus","conceptCode":"C43362","definition":"The lower opening of the digestive tract, lying in the cleft between the buttocks, through which fecal matter is extruded.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"High Grade Squamous Intraepithelial Neoplasia","conceptCode":"C8336","definition":"A precancerous neoplastic process characterized by the presence of moderate or severe dysplastic cytological changes which extend to the upper part of the squamous epithelium.  Maturation at the surface of the squamous epithelium may or may not be present.  Representative examples include the high grade esophageal squamous intraepithelial neoplasia, high grade cervical squamous intraepithelial neoplasia, high grade vaginal intraepithelial neoplasia, and high grade vulvar intraepithelial neoplasia.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBF189AC-B776-235A-E053-4EBD850ABB50","latestVersionIndicator":"Yes","beginDate":"2021-02-22","endDate":null,"createdBy":"COLLIED","dateCreated":"2021-02-22","modifiedBy":"ONEDATA","dateModified":"2021-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2736850","version":"1","preferredName":"Prior Therapeutic Procedure","preferredDefinition":"Earlier in time or order.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C25629:C49236","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4942A454-EC66-4C3B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-03-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2008-03-25","modifiedBy":"ONEDATA","dateModified":"2008-03-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBF189AC-B7E6-235A-E053-4EBD850ABB50","latestVersionIndicator":"Yes","beginDate":"2021-02-22","endDate":null,"createdBy":"COLLIED","dateCreated":"2021-02-22","modifiedBy":"COLLIED","dateModified":"2021-09-03","changeDescription":"Curated for AMC-112 protocol DC","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2531998","version":"1","preferredName":"Therapeutic Procedure Number","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._A numeral or string of numerals expressing value, quantity, or identification.","longName":"TX_NUM","context":"NHLBI","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","minLength":null,"maxLength":"10","minValue":null,"maxValue":null,"decimalPlace":"0","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2725537","version":"1","preferredName":"Therapeutic Procedure Number","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.:Number; a concept of quantity derived from zero and units; a numeral or string of numerals that is used for identification.","longName":"C49236:C25337","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Number","conceptCode":"C25337","definition":"A numeral or string of numerals expressing value, quantity, or identification.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"44F3EDCD-7054-2640-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-30","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-01-30","modifiedBy":"ONEDATA","dateModified":"2008-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"20A6DCCB-2E2E-24C3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-25","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-10-25","modifiedBy":"KUMMEROA","dateModified":"2017-11-02","changeDescription":"Added Class. Scheme and Origin 8/18/08sc.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"7283431","version":"1","longName":"CRF CDEs","context":"AMC","ClassificationSchemeItems":[{"publicId":"7283433","version":"1","longName":"Baseline Evaluations","context":"AMC"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"If \"Yes\", how many prior trea","type":"Preferred Question Text","description":"If \"Yes\", how many prior treatments for anal HSIL has the participant received in his/her lifetime?","url":null,"context":"AMC"}],"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBF1E691-DE61-2CA7-E053-4EBD850A07A3","latestVersionIndicator":"Yes","beginDate":"2021-02-22","endDate":null,"createdBy":"COLLIED","dateCreated":"2021-02-22","modifiedBy":"TSESU","dateModified":"2021-09-10","changeDescription":"Curated for AMC-112 protocol DC;  9/10/2021 - revised special character \" to display properly in caDSR. smt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}